Endra activates TAEUS system to initiate clinical study at LMU in Germany

ENDRA Life Sciences (NDRA) Inannounces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich… LMU University Hospital is one of Europe’s most highly regarded and influential academic research institutions and we are delighted to commence this partnership. This collaboration is expected to build upon ENDRA’s growing portfolio of clinical data and support the company’s FDA De Novo submission targeted for mid-2025. Further, we believe the data will support the adoption of TAEUS technology as the reliable and accurate biomarker for liver fat, marking it as a first strategic step into Germany’s healthcare market, the largest in Europe,” stated Alexander Tokman, Acting Chief Executive Officer of ENDRA and Chairman of the Board…This collaboration is expected to build upon ENDRA’s growing portfolio of clinical data and support the company’s FDA De Novo submission targeted for mid-2025.”